Since 1987, ORIGIO has been a global leader in delivering innovative Assisted Reproductive Technology (ART) solutions that enhance the work of ART professionals to the benefit of individuals.

In 2012, ORIGIO was acquired by The Cooper Companies Inc. and became part of CooperSurgical, a global leader in medical devices for women’s health.

In 2015 and 2016, ORIGIO joined forces with The Pipette Company, Research Instruments (RI), K-Systems, Reprogenetics, Recombine , Genesis Genetics and Wallace all companies acquired by The Cooper Companies Inc. to strengthen the footprint in the ART and genomics segments.

Our combined product range as CooperSurgical companies, includes pipettes, media and andrology products, and dedicated ART equipment, as well as a state-of-the-art electronic witnessing system. Our pioneering genetics services use cutting-edge technologies and genetic counselling services to assist ART clinics in making informed medical decisions.

Our world leading laboratories specialize in preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD), as well as carrier screening and non-invasive prenatal testing. We provide a complete solution for all genetic testing needs.

Our broad portfolio of products and services as well as our hands-on training and education program, are being developed together, to work in synergy. We continuously work in partnerships with experts and clinics across the globe to help improve customer success rates by offering next generation ART solutions for the entire IVF process.

With 16 subsidiaries and a global network of distributors, ORIGIO has a strong presence worldwide.

Headquartered in Denmark, ORIGIO employs over 400 people across the world.

Find your local ORIGIO contact.